Cancer Treatment Expenditures – EOM Aug 2026

Via The Ethical Skeptic: “As of end of month August 2026 cancer treatment continues its robust escalation in PPI-Neoplasm Treatment volume. This is expressed in Constant Dollars – all price escalations and inflation are removed. $53 billion in added consumer burden from cancer. We continue to substantiate a 3.5% CAGR and an elevation of 28%, which arrived commensurate with the rollout of the Covid-19 mRNA vaccine.

(3) Ethical Skeptic ☀ on X: “Cancer Treatment Expenditures – EOM Aug 2026 As of end of month August 2026 cancer treatment continues its robust escalation in PPI-Neoplasm Treatment volume. This is expressed in Constant Dollars – all price escalations and inflation are removed. $53 billion in added consumer https://t.co/XqDtPlc5P1” / X

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

Discover more from Lighthouse Economics

Subscribe now to keep reading and get access to the full archive.

Continue reading